Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Arcutis Biotherapeutics, Inc.
Age
2–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants legally competent to sign and give informed consent and if appropriate assent as required by local laws
Males and females ages 2 years and older (inclusive)
Clinical diagnosis of psoriasis vulgaris of at least 6 months duration (3 months for children) as determined by the Investigator
Females of childbearing potential (FOCBP) must have a negative pregnancy test at Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial.
In good health as judged by the Investigator, based on medical history, physical examination, serum chemistry labs, hematology values, and urinalysis.
Subjects considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.
You may not be if
Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.
Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
Previous treatment with ARQ-151 or its active ingredient
Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of investigational product
Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation
Clareo Health | Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
